Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs NIO Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while NIO Inc. trades at $3.4 (market cap $8.76B). The key difference: NIO Inc. is far larger — about 9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NIO Inc. for 81 Days on average.
| MRVI | NIO | |
|---|---|---|
Market Cap | $977.37M | $8.76B |
Volume | 2,742,564 | 36,159,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $7.42 |
52-Week Low | $2.83 | $3.37 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $1.08B | $6.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NIO trades at $3.56, up 2.59% today, but remains near 52-week lows amid a bearish technical trend. The company reported Q3 2026 deliveries up 25.4% and has beaten EPS estimates for three consecutive quarters, yet continues to post net losses with a -4.17% margin. A strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38 billion, though it initially weighed on the stock. Revenue growth is robust, reaching $87.49 billion in 2025, but profitability challenges and high debt levels persist.
The outlook is mixed: analyst consensus is bullish with a $6.23 price target, but execution risks in a competitive EV market and persistent cash burn pose significant hurdles. Upside depends on margin improvement and successful scaling of the battery-swap ecosystem, while downside risks include prolonged losses and industry price wars.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
